Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the safety profile of bevacizumab when combined with standard chemotherapy as first-line treatment of advanced or recurrent non-squamous NSCLC. In particular, the incidence of serious adverse events (SAEs) related to bevacizumab and the incidence of specific AEs (serious and non-serious) such as hypertension, proteinuria, wound healing complications, gastrointestinal perforations, arterial and venous thomboembolic events, haemoptysis, CNS bleeding, other haemorrhages and CHF will be investigated.
Critère d'inclusion
- Advanced or recurrent non-squamous non-small cell lung cancer